Acquired Fibrinogen Deficiency (AFD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Acquired fibrinogen deficiency (AFD), often linked with significant blood loss, presents a recurrent challenge in critical care scenarios. Fibrinogen plays a pivotal role in clot formation, as a crucial protein for initiating and maintaining coagulation. Typically, normal fibrinogen levels range from 1.5 to 4.5 g/l, with increases observed during pregnancy. However, fibrinogen is notably the first clotting factor to decrease to critically low levels in cases of severe bleeding. Moreover, significant blood loss can exhaust the body’s fibrinogen reserves. Conditions such as circulatory shock, certain carcinomas (e.g., prostate cancer), or sepsis can lead to excessive fibrinogen consumption, resulting in continuous clot formation and depletion of coagulation factors, ultimately leading to fibrinogen deficiency. Instances of low fibrinogen levels due to high fibrinogen usage are commonly associated with profuse bleeding or trauma during surgical procedures or accidents. Hypofibrinogenemia is recognized as a significant bleeding risk factor across various medical contexts, notably in trauma, obstetrics, and cardiovascular surgery. In France, Clottafact, a fibrinogen concentrate, has been approved for use in cases of massive bleeding associated with acquired fibrinogen deficiency.

Thelansis’s “Acquired Fibrinogen Deficiency (AFD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acquired Fibrinogen Deficiency (AFD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Acquired Fibrinogen Deficiency (AFD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Acquired Fibrinogen Deficiency (AFD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Acquired Fibrinogen Deficiency (AFD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033